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Background/aim: The Cancer Fatigue Scale (CFS) was developed to evaluate the severity of fatigue in patients with breast cancer. The
aim of this study is to translate and culturally adapt a Turkish version and investigate the validity and reliability of the CFS in Turkish
patients with fatigue symptoms.
Materials and methods: Eighty participants completed the Turkish version of the CFS for breast cancer and the European Organization
for Research and Treatment of Cancer Quality of Life Core Questionnaire “Core 30” (EORTC QLQ-C30). Test–retest reliability was
evaluated by repeating the CFS with a 7-day interval.
Results: The CFS demonstrated high test–retest reliability (ICC = 0.95) and good internal consistency (Cronbach’s alpha = 0.74) for all
domains. The Kaiser–Meyer–Olkin measure of sampling adequacy was found to be 0.819, which is considered to be satisfactory (>0.5).
Correlations between domains of CFS physical and EORTC physical (r: 0.77), CFS cognitive and EORTC cognitive (r: 0.70), and CFS
physical and EORTC fatigue (r: 0.80) were found to be significant.
Conclusion: The Turkish version of the CFS is a reliable and valid instrument to assess physical, effective, and cognitive dimensions of
fatigue. The CFS may be used to evaluate the severity of fatigue in Turkish-speaking breast cancer patients.
Key words: Breast cancer, fatigue, reliability, validity, Turkish

1. Introduction
Fatigue is one of the most common symptoms among
cancer patients. It is reported that fatigue frequency
ranges between 34% and 76% among cancer survivors.
The National Comprehensive Cancer Network defines
cancer-related fatigue as a persistent feeling of increase in
tiredness and decrease of energy and performance, lack of
energy or motivation, and problems with concentration
(1). Studies showed that the prevalence of fatigue among
breast cancer patients is greater than 50% or approximately
one in three patients (2,3). Goedendorp et al. showed that
patients with breast cancer tend to report higher levels of
fatigue compared to other types of cancer (4). The etiology
of fatigue in patients with breast cancer is not fully known,
so it is not possible to mention a single etiologic factor.
Female sex, age, and undergoing radiotherapy and/or
chemotherapy are thought increase the risk for fatigue in
breast cancer (5). Among these studies, about half have
found no relationship between age and fatigue, whereas
the other half reported that being younger is associated
with fatigue. Additionally, few studies have substantiated
* Correspondence: sedefkarayazgan88@hotmail.com
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the view that fatigue is associated with marital status and
education level (6). It is known that severity of fatigue is
affected by demographic characteristics and treatments
and their side effects. However, it is also important to
consider dietary habits, environmental factors, and one’s
lifestyle.
Fatigue is a multidimensional problem that can
affect patients’ physical, emotional, social, and cognitive
functioning at various degrees, and it usually causes a
noticeable decrease in the quality levels of everyday lives
of patients (7). It is known that fatigue affects patients
at varying degrees, and it is necessary to assess this
multidimensionally. Commonly used multidimensional
scales for assessing cancer-related fatigue in patients with
breast cancer are the Rhoton Fatigue Scale, Piper Fatigue
Scale, Multidimensional Fatigue Inventory, and Cancer
Fatigue Scale (CFS) (8–11).
The CFS was developed in Japan in 2000 by Okuyama
et al. The scale consists of three subheadings: physical,
emotional, and cognitive, with a total of 15 items. It has
been used in several studies with cancer patients so far
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(11–13). Previous studies have shown that as well as the
original Japanese version, German, Chinese, Arabic, and
Greek versions are reliable and valid for different cancer
populations (14–17). The CFS is an assessment that gives
information about bio-psycho-social factors on fatigue in
cancer and it is widely used in cancer research. In clinical
settings, limited time requirements and easy scoring of the
test are the greatest advantages of the CFS among other
cancer fatigue scales. Therefore, the purpose of this study
is to assess the reliability and the validity of the crosscultural adapted Turkish translation of the CFS among
patients with breast cancer.
2. Materials and methods
At the beginning of the study, the permission of the authors
of the original version of the CFS was received to translate
and validate the scale in the Turkish language.
2.1. Study population
The study was conducted at the Oncology Department of
Hacettepe University Hospitals. Patients were eligible in
terms of meeting the following participation criteria: 1)
being between the ages of 18 and 64 years; (2) having breast
cancer in stage 1, 2, or 3; 3) not undergoing a radiotherapy
or chemotherapy session in at least the last 2 weeks; 4)
literate and willing to join the study. Patients were ineligible
if they: 1) had relapsed or were in palliative care; 2) were
suffering from cognitive disorders (mini mental state score
of <23); 3) showed neurological signs or clinical instability.
During the study process, 86 patients who were diagnosed
with breast cancer were screened as potential participants.
Six of the patients subsequently met exclusion criteria:
five did not come for the retest, and one requested to be
removed from the study. As a result, our study population
consisted of 80 patients with breast cancer.
2.2. Instruments
A sociodemographic form, the CFS, and the European
Organization for Research and Treatment of Cancer
Quality of Life Core Questionnaire Core 30 (EORTC
QLQ-C30 version) were filled out by all the participants. The
sociodemographic form was prepared by the researchers,
comprising questions about age, sex, marital status, stage
of breast cancer, and whether undergoing chemotherapy
(neoadjuvant and adjuvant) and radiotherapy at the
moment or not.
The CFS is a scale that was developed to measure
fatigue in Japanese patients, especially in breast cancer
patients. It includes three dimensions: physical, affective,
and cognitive. A five-point Likert scale (1–5) is used
for each question and the maximum score for the CFS
physical function (CFS-P) is 28 points, 16 points for the
CFS affective function (CFS-A), 16 points for the CFS
cognitive function (CFS-C), and 60 points for CFS total
(CFS-T) (18).

The EORTC QLQ-C30 is a widely used scale in cancer.
Validation of the Turkish version was carried out by
Guzelant et al. in 2004 (18). The EORTC QLQ-C30 is made
up of 30 items and includes general well-being, functional
difficulties, and symptom control. Likert-type scores from
1 (none) to 4 (very) are used for the first 28 of 30 items,
while Likert-type scores from 1 (very bad) to 7 (perfect)
are used for items 29 and 30. In the present research, the
EORTC QLQ-C30 was used as a gold-standard test to assess
the fatigue and physical-emotional-cognitive function
parameters of the participants. Low scores indicate high
quality of life, while high scores indicate low quality of life
in these sections. Items 10, 12, and 18 assess fatigue, items
1–5 assess physical function, items 21–25 assess emotional
function, and items 20–25 assess cognitive function (19).
2.3. Translation and cross-cultural adaptation
The CFS was translated from English to Turkish according
to the standard methodology recommended by Beaton
et al. (20). The translation was done by two independent
translators whose native languages were Turkish. After
synthesizing the translated versions with two native
speakers, the final version of the translation was developed.
The final Turkish version was translated back from Turkish
to English again by two native English speakers who could
speak Turkish fluently. This version was compared with
the original version for inconsistencies. There was no
inconsistency with the original version. The aim of crosscultural adaptation was to attain consistency in the content
and face validity between the original and translated
versions of the questionnaire. Only 1 item (Q4) of the
CFS was changed, from “becoming careless” to “becoming
distractible”, because the former expression has a different
meaning in the Turkish language. The scales to evaluate
the test–retest reliability were administered twice to 80
patients with breast cancer within a 7-day interval (21).
2.4. Statistical analysis
The CFS scale was tested for reliability using the Turkish
version administered to 80 patients with breast cancer.
The patients filled out the questionnaires twice in 7-day
intervals. Reliability analysis of all 15 items of the CFS
was carried out for all patients with IBM SPSS 23.0 to
determine item–item, item–total, and Cronbach’s alpha
reliability. Test–retest reliability of the CFS was evaluated
using Pearson correlation coefficients (>0.7 acceptable;
>0.8 good; >0.9 excellent). The internal consistency was
measured with Cronbach’s alpha, which measures the
degrees of items that make up the total score. An acceptable
value for Cronbach’s alpha is ≥0.7, but values of ≥0.8 are
good and ≥0.9 are excellent (22). The construct validity
of the scale was calculated by exploratory factor analysis
with varimax rotation. Pearson correlation coefficients
were calculated between the CFS total/subscale scores and
EORTC QLQ-C30 fatigue/physical/emotional/cognitive
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function subscale scores to determine criterion-related
validity.
3. Results
3.1. Descriptive statistics
A total of 80 patients with breast cancer completed the test
and retest assessments. The mean age of the participants
was 46.41 ± 10.31 years (min = 20, max = 64). Table 1
shows the demographic characteristics of patients. Most
patients were aged between 41 and 65 years (72.5%), had
a university degree (38.8%), and had the diagnosis for 6
months to 3 years (38.8%).
3.2. Reliability of the CFS
The test–retest correlation coefficients of each item and the
total score between the test and retest phases were found to
be excellent with an ICC value above 0.9 (P < 0.01) (Table
2).

Table 1. Demographic characteristics of the study population (N
= 80).
Variable

N

%

18–25

5

6.3

25–40

17

21.3

41–65

58

72.5

Primary school

9

11.3

Secondary school

17

21.3

High school

23

28.8

University

31

38.8

1

6

7.5

2

49

61.3

3

25

31.3

6 months to 3 years

31

38.8

4–6 years

25

31.3

7–10 years

19

23.8

>10 years

5

6.3

Yes

18

22.5

No

62

77.5

Yes

52

65

No

28

35

Age

Level of education

Stage

Time from diagnosis

Radiotherapy

Chemotherapy
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Table 3 shows mean scores of the items and the
correlations of item to item, subscales, and internal
consistency. Internal consistencies of the total fatigue scale
and the three subscales were found to be acceptable with
Cronbach’s alpha of 0.74.
3.3. Construct validity
The construct validity of the CFS was analyzed using
factor analysis with varimax rotation. Applicability of the
rotation was determined by the assumptions of the initial
factor analysis. Kaiser–Meyer–Olkin measure of sampling
adequacy was found to be 0.819, while Bartlett’s test of
sphericity had a result of 725.371 with P = 0.0001. These
results show that our study population for the CFS was
appropriate for factor analysis.
The Turkish CFS showed 3 factors in analysis in the
original version. These 3 factors explained a total of 69.03%
of the variance. In terms of item distribution according
to the factors, all items were similar to the original scale,
which means the three dimensions presented in the
original scale were also presented in the current Turkish
validity study (Table 4).
3.4. Criterion-related validity
Pearson correlation coefficients were computed between
all subtests of the CFS and EORTC QLQ-30 scale. The
EORTC QLQ-30 scale was particularly chosen because
it is carried out in accordance with the assessments
of the physical and cognitive functions of the patients
with cancer as well as their assessment of fatigue (23).
All subscales of the CFS and EORTC QLQ-30 subscales
were analyzed. Correlations were found to be in a range
between weak and strong in subscales, but not in between
CFS-P and EORTC cognitive function, and both CFS-C
and CFS-A with EORTC physical function. As far as the
criterion validity of the CFS is concerned, all correlations
were found to be signiﬁcant. The strongest correlation was
found between the CFS-P and EORTC fatigue subscales (
P < 0.001; r: 0.80) (Table 5).
4. Discussion
This study describes the translation and psychometric
testing in terms of reliability and validity (construct and
criterion-related) of the 3-factor and 15-item Turkish
version of the CFS. For all dimensions of the Turkish
version, the internal consistency of the CFS was found
to be acceptable (coefficient alpha values were ≥0.7). The
degree of internal consistency observed in the present
study (α = 0.74) was lower than that of the original
validation study (α = 0.88) (11). The low score in our study
could be due to inadequate sample size or inclusion of
just one type of cancer. However, Cronbach’s α values of
the physical (0.89), affective (0.93), and cognitive (0.84)
subscales of the CFS were higher than those of the original
study, which is thought to be due to the result of including
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Table 2. Mean scores and test–retest reliability of the CFS.
CFS

CFS-P

Before

After

Test–retest reliability

Mean

SD

Mean

SD

(ICC)

17.81

5.50

17.22

4.78

0.94*

CFS-A

7.58

2.35

7.82

2.17

0.93*

CFS-C

7.42

3.80

7.72

3.26

0.94*

CFS-T

32.82

7.33

32.77

6.41

0.95*

* P < 0.001, CFS: Cancer Fatigue Scale, CFS-P: Cancer Fatigue Scale-Physical, CFS-A: Cancer Fatigue
Scale-Affective, CFS-C: Cancer Fatigue Scale-Cognitive, CFS-T: Cancer Fatigue Scale-Total.
Table 3. Item, subscale, and scale descriptive and reliability measurements (N = 80).
Item

Mean

SD

α if item
deleted

Item/scale
correlation

Cronbach’s α

CFS- Total

17.81

5.50

-

-

0.74

CFS- P

*

*

-

-

0.89

Q1- Do you become tired easily?

3.60

1.14

0.89

0.65

-

Q2- Do you have the urge to lie down?

3.83

0.93

0.87

0.79

-

Q3- Do you feel exhausted?

3.76

0.88

0.88

0.68

-

Q6- Does your body feel heavy and tired?

3.63

1.02

0.88

0.71

Q9- Everything is too much?

3.31

0.94

0.88

0.71

Q12- Many things are too exhausting?

3.32

1.05

0.88

0.71

Q15- Do you feel such fatigue that you don’t know
what to do with yourself?

3.33

0.98

0.88

0.67

CFS-A

*

*

-

-

0.93

Q5- Do you feel energetic?

2.10

0.90

0.75

0.75

-

Q8- Do you feel interest in anything?

2.93

1.07

0.82

0.61

-

Q11- Can you concentrate on certain things?

2.55

0.85

0.81

0.60

-

Q14- Can you pull yourself together to do anything?

2.40

1.00

0.77

0.70

-

CFS-C

*

*

-

-

0.84

Q4- Do you think that you have a lack of concentration?

3.32

1.13

0.81

0.67

Q7- Do you feel that you more often make errors while
speaking?

2.80

1.07

0.76

0.79

Q10- Do you feel you have become forgetful?

2.82

0.96

0.84

0.58

Q13- Do you feel that your thinking has become slower?

2.47

1.37

0.79

0.74

*See Table 2 for mean scores; Q: Question, CFS: Cancer Fatigue Scale, CFS-P: Cancer Fatigue Scale-Physical, CFS-A: Cancer Fatigue
Scale-Affective, CFS-C: Cancer Fatigue Scale-Cognitive, CFS-T: Cancer Fatigue Scale-Total.

patients with a particular type of cancer. Compared to the
original validation study, three dimensions of the original
fatigue scale were available in the Turkish version with a
varimax rotation (11).
In the original study, the test–retest reliability result
was found to be r = 0.80, in the German version it was

r = 0.82, and in the Greek version it was r = 0.79 (all P <
0.001) (14,17). The perfect stability of the CFS original in
German and Greek versions was also found in our study
(r = 0.95, P < 0.001), and our result was comparable to
those of the previous validation studies. The mean scores
of the three dimensions were also found higher compared
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Table 4. Factor analysis of the CFS (N = 80).
Factor component
Factor 1 - physical
Q1

0.695

Q2

0.836

Q3

0.821

Q4

Factor 2 - cognitive

Factor 3 - affective

0.783

Q5

0.822

Q6

0.823

Q7

0.868

Q8

0.806

Q9

0.732

Q10

0.708

Q11

0.768

Q12

0.711

Q13

0.901

Q14

0.822

Q15

0.760

Eigenvalue after rotation

5.573

2.531

2.252

% variance explained after rotation

37.15%

16.82%

15.01%

Table 5. Criterion-related validity of the CFS.

CFS-T

EORTC Fatigue

EORTC Physical
function

EORTC Emotional
function

EORTC Cognitive
function

0.615**

0.570**

0.282**

0.438**

CFS-P

0.800**

0.772**

0.267*

0.126

CFS-A

0.398**

0.148

0.485**

0.345*

CFS-C

0.283*

0.152

0.231*

0.709*

* P < 0.05, ** P < 0.001, CFS: Cancer Fatigue Scale, CFS-P: Cancer Fatigue Scale-Physical, CFS-A: Cancer Fatigue
Scale-Affective, CFS-C: Cancer Fatigue Scale-Cognitive, CFS-T: Cancer Fatigue Scale-Total.

to all the other studies. While the other studies included
patients with different types of cancer, having patients with
one type of cancer is thought to be the reason for this high
score in the present study. Also, the literature indicates that
patients with breast cancer have the highest level of fatigue
compared to other cancer populations and it is thought
that this may lead to this high score as well (5,24,25). The
current validation study also provided evidence for the
criterion validity of the CFS in Turkish.
The CFS and EORTC QLQ-C30 were correlated
significantly in almost all of their subscales. The CFS-T
and EORTC fatigue, CFS-P and EORTC physical and
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fatigue, CFS-A and EORTC emotional, and CFS-C
and EORTC cognitive subscales were significantly and
positively correlated. The criterion validity was found to be
acceptable. According to Pearson correlation coefficients,
all three subscales were found to be acceptable, which
is comparable with other validation studies. In spite
of differences of methodology, the results indicate
that Turkish version of the CFS is consistent with the
consistency of the positive results of the previous CFS
version studies (11,14,16).
As in the previous validation studies, the sample size
is big enough to generalize Cronbach’s α score. Regarding
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the limitations of our study, the number of patients could
be kept higher to obtain a higher score. However, most
of the previous validation studies, except for the study of
Montazeri et al., included patients with various types of
cancer and not particularly breast cancer patients (14–16).
At this point, our study might provide a significant benefit
for fatigue assessment scales that are specifically tailored
to breast cancer. To clarify the validity and reliability of the
CFS, further studies with higher numbers of participants
should be planned.
In conclusion, the Turkish version of the CFS was
found to be a reliable and valid fatigue scale in patients with
breast cancer. This is an important and major contribution
to the literature, as it provides evidence of the reliability,

validity, and cross-cultural adaptation of the Turkish CFS
in patients with breast cancer. Additionally, with its good
internal consistency, the Turkish CFS can also be useful
for other types of cancer patients. In the literature, it is
seen that the number of unidimensional scales is more
than multidimensional scales that measure fatigue. As
fatigue is a multidimensional symptom, we suggest using
multidimensional scales such as the CFS, which might
inform clinicians or practitioners about both evaluations
and interventions with a broader perspective. The CFS
evaluates fatigue from a multidimensional perspective
in a brief and practical manner, which makes it more
significant than the other fatigue scales for patients with
breast cancer.
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